公开(公告)号：US20090215853A1

公开(公告)日：2009-08-27

申请号：US11579608

申请日：2005-05-19

申请人： John L. Hall ,  Sylvie Beljanski

发明人： John L. Hall ,  Sylvie Beljanski

IPC分类号： A61K31/405

CPC分类号： A61K36/24 ,  A61K31/475 ,  A61K2300/00

摘要： A method and composition for preventing prostate cancer and/or reducing PSA levels and/or alleviating the symptoms of BPH (Benign Prostatic Hyperplasia) or PIN (prostatic intraepithelial neoplasia) by administration of an effective amount of a mixture of flavopereirine and alstonine. A method and composition for treating low-grade prostate cancer and preventing the onset of metastatic disease and/or reducing the doubling time of PSA levels in men with positive biopsies showing relatively low Gleason scores and morphologies characteristic of non-invasive, slow-progressing prostate cancer. The flavopereirine and alstonine can be in the form of natural extracts derived from Pao Pereira and Rauwolfia Vomitoria, respectively. Alternatively, these two active compounds can be administered in purified form. The composition can be in included in a kit along with instructions for use in a treatment regimen.

摘要翻译： 通过施用有效量的黄曲霉素和阿尔斯汀的混合物，预防前列腺癌和/或降低PSA水平和/或减轻BPH（良性前列腺增生症）或PIN（前列腺上皮内瘤变）的症状的方法和组合物。 用于治疗低级前列腺癌并预防转移性疾病发作和/或减少具有阳性活组织检查的男性PSA水平倍增时间的方法和组合物显示出相对较低的格列森评分和非侵入性，缓慢进展的前列腺特征的形态 癌症。 黄曲霉素和阿司匹林可以分别是由派佩雷拉（Pao Pereira）和萝维（Rauwolfia Vomitoria）衍生的天然提取物。 或者，这两种活性化合物可以以纯化形式施用。 组合物可以包含在试剂盒中以及用于治疗方案的说明书中。

公开(公告)号：US20080233121A1

公开(公告)日：2008-09-25

申请号：US11978014

申请日：2007-10-26

申请人： Sylvie Beljanski ,  John Hall

发明人： Sylvie Beljanski ,  John Hall

IPC分类号： A61K39/395 ,  A61K31/7105 ,  A61P35/00

CPC分类号： A61K31/7105 ,  A61K9/006 ,  A61K31/7088 ,  A61K45/06 ,  A61K47/10 ,  Y02A50/473 ,  A61K2300/00

摘要： This invention provides therapeutic treatments that prevent or ameliorate thrombocytopenia based on administration of small RNA fragments. More specifically, this invention provides an improved chemotherapeutic regimen that prevents or ameliorates bone marrow suppression and thrombocytopenia induced by anti-cancer drugs, wherein the chemotherapeutic regimen incorporates administration of small RNA fragments. Further, the present invention provides a therapeutic treatment for thrombocytopenia associated with immune disorders known as Immune Thrombocytopenic Purpura based on administration of small RNA fragments.

摘要翻译： 本发明提供了基于施用小RNA片段来预防或改善血小板减少症的治疗性治疗。 更具体地，本发明提供了改进的化疗方案，其防止或改善由抗癌药物诱导的骨髓抑制和血小板减少症，其中化疗方案包括施用小RNA片段。 此外，本发明提供了一种治疗性治疗血小板减少症，与基于小RNA片段的施用相关的称为免疫性血小板减少性紫癜的免疫疾病相关。

公开(公告)号：US20050266107A1

公开(公告)日：2005-12-01

申请号：US11132183

申请日：2005-05-19

申请人： John Hall ,  Sylvie Beljanski

发明人： John Hall ,  Sylvie Beljanski

IPC分类号： A61K31/475 ,  A61K35/00 ,  A61K36/24 ,  A61P35/00 ,  A61K35/78

CPC分类号： A61K36/24 ,  A61K31/475 ,  A61K2300/00

摘要： A method and composition for preventing prostate cancer and/or reducing PSA levels and/or alleviating the symptoms of BPH (Benign Prostatic Hyperplasia) or PIN (prostatic intraepithelial neoplasia) by administration of an effective amount of a mixture of flavopereirine and alstonine. A method and composition for treating low-grade prostate cancer and preventing the onset of metastatic disease and/or reducing the doubling time of PSA levels in men with positive biopsies showing relatively low Gleason scores and morphologies characteristic of non-invasive, slow-progressing prostate cancer. The flavopereirine and alstonine can be in the form of natural extracts derived from Pao Pereira and Rauwolfia Vomitoria, respectively. Alternatively, these two active compounds can be administered in purified form. The composition can be in included in a kit along with instructions for use in a treatment regimen.

摘要翻译： 通过施用有效量的黄曲霉素和阿尔斯汀的混合物，预防前列腺癌和/或降低PSA水平和/或减轻BPH（良性前列腺增生症）或PIN（前列腺上皮内瘤变）的症状的方法和组合物。 用于治疗低级前列腺癌并预防转移性疾病发作和/或减少具有阳性活组织检查的男性PSA水平倍增时间的方法和组合物显示出相对较低的格列森评分和非侵入性，缓慢进展的前列腺特征的形态 癌症。 黄曲霉素和阿司匹林可以分别是由派佩雷拉（Pao Pereira）和萝维（Rauwolfia Vomitoria）衍生的天然提取物。 或者，这两种活性化合物可以以纯化形式施用。 组合物可以包含在试剂盒中以及用于治疗方案的说明书中。